Results 151 to 160 of about 24,050 (249)

Advances in Artificial Intelligence for Glioblastoma Radiotherapy Planning and Treatment. [PDF]

Cancers (Basel)
Master R, Rubin N, Sampson J, Yadav KK, Pandita S, Sabbagh A, Krishnan A, Silva PJ, Ramos KS, Gregoire V, Paragios N, Krishnan S, Pandita TK.   +12 more
europepmc   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Maintaining quality of scientific peer-review and publishing in <i>Physics and Imaging in Radiation Oncology</i>. [PDF]

Phys Imaging Radiat Oncol
Knäusl B, Solberg TD, Thorwarth D, Muren LP.   +3 more
europepmc   +1 more source

Living at genetic risk: The patient experience of Lynch syndrome

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome is a germline cancer predisposition syndrome caused by a variant in one of four genes. Lynch syndrome places individuals at significantly higher risk for a range of cancers, especially colorectal and endometrial. Depending on which gene is affected, the risk of ovarian, gastric, small bowel, pancreatic, biliary urothelial, brain,
Nicola Reents, Georgina Hoffmann, Kelly Kohut   +2 more
wiley   +1 more source

Radiomics and artificial intelligence in precision radiotherapy for cervical cancer: a narrative review. [PDF]

Front Oncol
He Y, Lu Y, Hu L.
europepmc   +1 more source

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, EarlyView.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Impact of CT calibration curves on radiotherapy planning using diagnostic CT scans and a planning CT supporting DirectDensity reconstruction. [PDF]

J Appl Clin Med Phys
Krause F, Siebert FA.
europepmc   +1 more source

Patient‐ and caregiver‐reported barriers to radiotherapy for cancer in sub‐Saharan Africa—A survey of population‐based registries

International Journal of Cancer, EarlyView.
What's New? Low‐ and middle‐income countries have over 70% of the global cancer burden but 10% of the world's radiotherapy capacities. This population‐based multi‐country study explores the barriers to access experienced by cancer patients in sub‐Saharan Africa.
Eric Sven Kroeber, Tamara König, Ole Stöter, Biying Liu, Phoebe Mary Amulen, Margaret Borok, Gladys Chesumbai, Eric Chokunonga, Ima‐Obong Ekanem, Mahine Ivanga, Bakarou Kamaté, William Muller, Abidemi Omonisi, Jean‐Félix Peko, Mathewos Assefa, Furaha Serventi, Markus Wallwiener, Mazvita Muchengeti, Pablo Sandro Carvalho Santos, Donald Maxwell Parkin, Eva Johanna Kantelhardt, Nikolaus Christian Simon Mezger   +21 more
wiley   +1 more source

AI-assisted cryo-dose estimation and tissue injury modeling for assessing side effects in MRI-guided prostate cryoablation: a retrospective study. [PDF]

Phys Med Biol
Moreira P, Ma M, Fordham N, Vangel M, Tempany C, Tuncali K, Tokuda J.   +6 more
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source